Disease relevance of dichloroplatinum

• Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study [1].
• Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro [2].
• Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloroplatinum or the angiogenesis inhibitor AGM-1470 [3].
• Cellular uptake and toxicity study of cis-bis(6-aminoquinoline) dichloroplatinum (II) [4].
• Systemic hypertension: complication of intra-arterial cis-diammine dichloroplatinum (II) infusion [5].

High impact information on dichloroplatinum

• Here, we evaluate the combined efficacy of two antisense oligonucleotides targeting bcl-2 mRNA (ODN bcl-2) and c-myc mRNA (ODN c-myc) in combination with cis-diammine dichloroplatinum (cisplatin, DDP) on three human melanoma lines (LM, NG, and M20) [6].
• Differentiation-specific nuclear matrix proteins cross-linked to DNA by cis-diammine dichloroplatinum [7].
• In these cells, treatment with a "high" bolus dose of platinum complex over finite exposure times is often less cytotoxic than treatment with lower doses of the same compound but over a continuous exposure time, although the cells are subjected to the same AUC of dichloroplatinum complex [8].
• DNA-protein cross-linkages were produced in intact nuclei of chicken erythrocytes by the action of cis-diammine dichloroplatinum [9].
• EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway [10].

Chemical compound and disease context of dichloroplatinum

• After a 24 hour exposure to hypoxia, drugs 1, 3-bis, 2-chloroethyl-1-nitrosurea (BCNU) and cis-diammine, dichloroplatinum II (CDDP) were administered, and cell survival was determined [11].

Biological context of dichloroplatinum

• Cis-diammine dichloroplatinum (DDP) 120 mg/m2 iv was given after prehydration, with mannitol diuresis on Day 1 [12].

Anatomical context of dichloroplatinum

• Nevertheless, a relationship was found between the AUC of a dichloroplatinum complex in medium and the efficacy of the compound in the MCF-7 cell line [8].
• Six female patients with medullary thyroid carcinoma were treated with doxorubicin (50 mg/m2) and cis-diammine dichloroplatinum (70 mg/m2) every three weeks [13].

Associations of dichloroplatinum with other chemical compounds

• METHODS: A six-year-old girl underwent corneal tattooing (platinum chloride reduced by hydrazine) in the relevant scarred corneal sector [14].
• Fluorescence decay of ethidium bromide in the presence of the Z-conformation of poly(dG-dC) and of poly(dG-dC) modified by chlorodiethylenetriamine platinum(II) chloride [15].

Gene context of dichloroplatinum

• Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma [16].
• Mg2+ dependent ATPase activity was greatly inhibited (82%) by the specific inhibitors of vaculor proton translocating ATPase; Cis-didimethylsulfoxide dichloroplatinum (II) at approximately 90 microM and bafilomycin AI at two fold higher concentrations [17].
• OBJECTIVES: Chloroplatinates are potent allergens but other soluble platinum compounds such as tetraammine platinum dichloride (TPC) do not provoke reactions in subjects who are sensitive to chloroplatinates [18].

Analytical, diagnostic and therapeutic context of dichloroplatinum

• Cis-diamine dichloroplatinum (II) (DDP) injected i.p. or i.v. at the dosage of 0.83 mg/kg to BALB/c mice on days 0, 7 and 14 elicited antibodies against proteins (RSA, BGG) and haptens (TNP, FITC) detectable by ELISA or by passive haemagglutination [19].

References